A phase I/II study of cancer peptide vaccine S-288310 in patients with advanced urothelial carcinoma of the bladder

W. Obara, M. Eto, H. Mimata, K. Kohri, N. Mitsuhata, I. Miura, T. Shuin, T. Miki, T. Koie, H. Fujimoto, K. Minami, Y. Enomoto, T. Nasu, T. Yoshida, H. Fuse, I. Hara, K. Kawaguchi, A. Arimura, T. Fujioka

研究成果: ジャーナルへの寄稿記事

21 引用 (Scopus)

抜粋

Background: S-288310, a cancer peptide vaccine composed of two HLA-A*24:02-restricted peptides derived from two oncoantigens, DEP domain-containing 1 (DEPDC1) and M-phase phosphoprotein 1 (MPHOSPH1), was investigated in urothelial carcinoma (UC) of the bladder. Patients and methods: Thirty eight HLA-A*24:02-positive patients with progressive UC were enrolled in this study. In the phase I part of the study, three patients each were treated with S-288310 at 1mg or 2 mg/peptide subcutaneously once a week to evaluate safety and tolerability. In the phase II, 32 patients were randomized to receive either 1mg or 2mg to evaluate the difference in cytotoxic T lymphocytes (CTL) induction and safety. Results: S-288310 was safe and well tolerated in the phase I. Of 27 patients evaluable for immune responses in the phase II, there was no difference in CTL induction rate between the 1mg (100%) and 2mg (80.0%) groups. Of 32 patients receiving S-288310 in the phase II, the most frequent drug-related AE was the injection site reaction that was observed in 29 patients (90.6%), but none of the patients discontinued administration due to these reactions and no dose relationship in the frequency and severity was observed. The objective response rate of the 32 patients was 6.3% and the disease control rate was 56.3%. The median overall survival (OS) rates for patients vaccinated with S-288310 after one regimen of chemotherapy, 2 regimens, or 3 or more were 14.4, 9.1 and 3.7 months, respectively, and 32.2% of patients post first-line treatment were alive at 2 years. OS of patients who showed CTL induction to both peptides was longer than that of those with CTL induction to no or one peptide. Conclusion: S-288310 was well-tolerated and effectively induced peptide-specific CTLs, which were correlated with longer survival for patients with UC of the bladder. Trial registration ID: JapicCTI-090980

元の言語英語
ページ(範囲)798-803
ページ数6
ジャーナルAnnals of Oncology
28
発行部数4
DOI
出版物ステータス出版済み - 4 1 2017
外部発表Yes

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology

フィンガープリント A phase I/II study of cancer peptide vaccine S-288310 in patients with advanced urothelial carcinoma of the bladder' の研究トピックを掘り下げます。これらはともに一意のフィンガープリントを構成します。

  • これを引用

    Obara, W., Eto, M., Mimata, H., Kohri, K., Mitsuhata, N., Miura, I., Shuin, T., Miki, T., Koie, T., Fujimoto, H., Minami, K., Enomoto, Y., Nasu, T., Yoshida, T., Fuse, H., Hara, I., Kawaguchi, K., Arimura, A., & Fujioka, T. (2017). A phase I/II study of cancer peptide vaccine S-288310 in patients with advanced urothelial carcinoma of the bladder. Annals of Oncology, 28(4), 798-803. https://doi.org/10.1093/annonc/mdw675